2253 related articles for article (PubMed ID: 2470152)
1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Slamon DJ; Godolphin W; Jones LA; Holt JA; Wong SG; Keith DE; Levin WJ; Stuart SG; Udove J; Ullrich A
Science; 1989 May; 244(4905):707-12. PubMed ID: 2470152
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
[TBL] [Abstract][Full Text] [Related]
3. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma.
Naber SP; Tsutsumi Y; Yin S; Zolnay SA; Mobtaker H; Marks PJ; McKenzie SJ; DeLellis RA; Wolfe HJ
Am J Clin Pathol; 1990 Aug; 94(2):125-36. PubMed ID: 1973590
[TBL] [Abstract][Full Text] [Related]
5. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.
Kury FD; Schneeberger C; Sliutz G; Kubista E; Salzer H; Medl M; Leodolter S; Swoboda H; Zeillinger R; Spona J
Oncogene; 1990 Sep; 5(9):1403-8. PubMed ID: 1699198
[TBL] [Abstract][Full Text] [Related]
6. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu oncogene protein and prognosis in breast cancer.
Tandon AK; Clark GM; Chamness GC; Ullrich A; McGuire WL
J Clin Oncol; 1989 Aug; 7(8):1120-8. PubMed ID: 2569032
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer.
Hung MC; Zhang X; Yan DH; Zhang HZ; He GP; Zhang TQ; Shi DR
Cancer Lett; 1992 Jan; 61(2):95-103. PubMed ID: 1346099
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
Bellacosa A; de Feo D; Godwin AK; Bell DW; Cheng JQ; Altomare DA; Wan M; Dubeau L; Scambia G; Masciullo V; Ferrandina G; Benedetti Panici P; Mancuso S; Neri G; Testa JR
Int J Cancer; 1995 Aug; 64(4):280-5. PubMed ID: 7657393
[TBL] [Abstract][Full Text] [Related]
10. Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR.
Knyazev PG; Imyanitov EN; Chernitca OI; Nikiforova IF; Hanson KP
Oncology; 1992; 49(2):162-5. PubMed ID: 1349430
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Borg A; Tandon AK; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Killander D; McGuire WL
Cancer Res; 1990 Jul; 50(14):4332-7. PubMed ID: 1973070
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of p185 is not related to erbB2 amplification in ovarian cancer.
Morali F; Cattabeni M; Tagliabue E; Campiglio M; Menard S; Marzola M; Lucchini V; Colombo N; Mangioni C; Redaelli L
Ann Oncol; 1993 Nov; 4(9):775-9. PubMed ID: 7904177
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu oncogene expression and proliferation in breast cancers.
Bacus SS; Ruby SG; Weinberg DS; Chin D; Ortiz R; Bacus JW
Am J Pathol; 1990 Jul; 137(1):103-11. PubMed ID: 1973597
[TBL] [Abstract][Full Text] [Related]
15. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract][Full Text] [Related]
16. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.
Oh JJ; Grosshans DR; Wong SG; Slamon DJ
Nucleic Acids Res; 1999 Oct; 27(20):4008-17. PubMed ID: 10497265
[TBL] [Abstract][Full Text] [Related]
17. Gene signals relapse of breast, ovarian cancers.
Marx JL
Science; 1989 May; 244(4905):654-5. PubMed ID: 2566202
[No Abstract] [Full Text] [Related]
18. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer.
Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ
Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629
[TBL] [Abstract][Full Text] [Related]
19. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
